ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1226

Effect of New Method for Pre-Administration Assessment of Intravenous Biologics on Infections in Patients with Rheumatoid Arthritis

Sho Fukui1, Masei Suda2, Haruki Sawada3, Yukihiko Ikeda1, Mitsuru Watanabe4, Ayako Koido4, Rui Kawato5, Yasuhiro Suyama6, Hisanori Shimizu7, Haruyuki Yanaoka7, Ryo Rokutanda1, Hiromichi Tamaki1, Tokutaro Tsuda1, Ken-ichi Yamaguchi8, Mitsumasa Kishimoto1 and Masato Okada9, 1Immuno-Rheumatology Center, St. Luke's International Hospital, Tokyo, Japan, 2Immuno-Rheumatology Center, St luke's International hospital, Tokyo, Japan, 3Immuno-rheumatology Center, St. Luke's International Hospital, Tokyo, Japan, 4Immune-Rheumatology Center, St. Luke's International Hospital, Tokyo, Japan, 5Immuno rheumatology center, St. Luke's International Hospital, Tokyo, Japan, 6Division of Rheumatology, JR Tokyo General Hospital, Tokyo, Japan, 7St. Luke's International Hospital, Tokyo, Japan, 8Allergy and Rheumatology, St. Luke's International Hospital, Tokyo, Japan, 9Immuno-Rheumatology Center, St. Luke’s International Hospital, Tokyo, Japan

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Biologic agents, infection and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, October 22, 2018

Title: Infection-related Rheumatic Disease Poster

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose:

Biologics are widely used and effective treatments for rheumatoid arthritis (RA), but generally biologics are avoided when patients have active infections on the day of administration.

In Japan, nurses are not authorized to assess whether patients have active infections or not. In our hospital, doctors in charge of the pre-administration assessments conventionally checked patient’s status by taking history and physical examinations on the day of intravenous biologics, but it does not seem to be time efficient. We implemented new method in which nurses systematically screen according to pre-determined questionnaires on infections before doctors see patients. Our aim of this study is to reveal effectiveness of this new method of assessments.

Methods:

We retrospectively review charts of patients with RA who received intravenous biologics at our hospital in Tokyo, Japan from June 2016 to April 2018. We investigated basic demographics, kinds of biologics and other treatments, underlying diseases, numbers and sites of serious infection(SI), and opportunistic infections. SI was defined as infections requiring intravenous antibiotics, hospitalization, or resulting in death. We compared numbers of infections in the new method with those in conventional one. Univariate analysis and Chi-square test were performed.

We also calculated the number of scheduled administrations and evaluated results of screening by nurse and doctor’s assessment.

Results:

We identified 360 cases in total. There are 189 and 171 patients who received intravenous biologics from June 2016 to May 2017 with conventional assessment and from June 2017 to April 2018 with new-style assessment.

The baseline characteristics are shown in table 1. Though there are no significant differences in the number of SI between new and conventional methods, the rate of SI was 4.4% and lower than that reported in previous studies.

The number of scheduled administration of biologics and its decision after assessments by nurse and doctors are shown in figure 1. There was just 1 case in which doctors postponed biologics even the patient was assessed not to have active infections by nurse.

Conclusion:

Systematical screening by nurse with pre-determined questionnaires is very sensitive so that doctors can carefully see cases in which infections are suspected by the screening. Our new-method of pre-administration assessments can contribute to time-efficient practice without any increasing risk of SI.


Disclosure: S. Fukui, None; M. Suda, None; H. Sawada, None; Y. Ikeda, None; M. Watanabe, None; A. Koido, None; R. Kawato, None; Y. Suyama, None; H. Shimizu, None; H. Yanaoka, None; R. Rokutanda, None; H. Tamaki, None; T. Tsuda, None; K. I. Yamaguchi, None; M. Kishimoto, None; M. Okada, None.

To cite this abstract in AMA style:

Fukui S, Suda M, Sawada H, Ikeda Y, Watanabe M, Koido A, Kawato R, Suyama Y, Shimizu H, Yanaoka H, Rokutanda R, Tamaki H, Tsuda T, Yamaguchi KI, Kishimoto M, Okada M. Effect of New Method for Pre-Administration Assessment of Intravenous Biologics on Infections in Patients with Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/effect-of-new-method-for-pre-administration-assessment-of-intravenous-biologics-on-infections-in-patients-with-rheumatoid-arthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/effect-of-new-method-for-pre-administration-assessment-of-intravenous-biologics-on-infections-in-patients-with-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology